These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
167 related items for PubMed ID: 21449676
21. [Antidepressants consumption in the global population in France]. Olié JP, Elomari F, Spadone C, Lépine JP. Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542 [Abstract] [Full Text] [Related]
22. Polymorphisms of stress pathway genes and emergence of suicidal ideation at antidepressant treatment onset. Nobile B, Ramoz N, Jaussent I, Dubois J, Guillaume S, Gorwood P, Courtet P. Transl Psychiatry; 2020 Sep 20; 10(1):320. PubMed ID: 32952155 [Abstract] [Full Text] [Related]
23. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. Baldwin DS, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, Pover GH, Ascher A. J Clin Psychiatry; 1996 Sep 20; 57 Suppl 2():46-52. PubMed ID: 8626363 [Abstract] [Full Text] [Related]
24. Suicidal ideation during antidepressant treatment: do genetic predictors exist? Perroud N. CNS Drugs; 2011 Jun 01; 25(6):459-71. PubMed ID: 21649447 [Abstract] [Full Text] [Related]
27. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Malhi GS, Ng F, Berk M. Aust N Z J Psychiatry; 2008 Apr 01; 42(4):346-9. PubMed ID: 18330778 [Abstract] [Full Text] [Related]
28. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, Yi Z, Hong W, Wang Y, Jiang K, Gao K, Cui X, Nierenberg AA, OPERATION Study Team. J Clin Psychopharmacol; 2010 Aug 01; 30(4):357-64. PubMed ID: 20571433 [Abstract] [Full Text] [Related]
32. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM. J Clin Psychopharmacol; 2008 Apr 01; 28(2):156-65. PubMed ID: 18344725 [Abstract] [Full Text] [Related]
33. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Wolfersdorf M, Barg T, König F, Leibfarth M, Grünewald I. Pharmacopsychiatry; 1995 Mar 01; 28(2):56-60. PubMed ID: 7624387 [Abstract] [Full Text] [Related]
37. Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans. Gassen NC, Hartmann J, Zschocke J, Stepan J, Hafner K, Zellner A, Kirmeier T, Kollmannsberger L, Wagner KV, Dedic N, Balsevich G, Deussing JM, Kloiber S, Lucae S, Holsboer F, Eder M, Uhr M, Ising M, Schmidt MV, Rein T. PLoS Med; 2014 Nov 01; 11(11):e1001755. PubMed ID: 25386878 [Abstract] [Full Text] [Related]
38. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord; 1990 Apr 01; 18(4):289-99. PubMed ID: 2140382 [Abstract] [Full Text] [Related]
40. FKBP5 polymorphisms and antidepressant response in geriatric depression. Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GM. Am J Med Genet B Neuropsychiatr Genet; 2010 Mar 05; 153B(2):554-560. PubMed ID: 19676097 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]